141 results
Page 2 of 8
6-K
EX-99
qjvqcq
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
gj58sjfmlzu ualhd
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
na0yh qtgm
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
tpgvi11b 15b13ji
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
pg4mikw9xj huq
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
elagdtlxkrmq
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
qqs8u
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
ipr3d5x918 xaw
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-1
6rvvnj8kfdjiq f2h5
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
n5phjevrgdgmtzyh38
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
ui3y6608ut
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
b0lmgl63me4
25 Apr 23
Current report (foreign)
7:07am
6-K
EX-99
r6f6zq 5ynj1
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-10.1
jkonj1 345g1k0p
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-99
h032m
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-10.1
5ig8idqk87y
3 Sep 21
Current report (foreign)
4:30pm
424B5
dc9s9 g10j
3 Sep 21
Prospectus supplement for primary offering
4:29pm